IP Library Granted Patent US 10,898,517
Granted Patent B2
US 10,898,517 · App. 16/791,697 · Granted Jan 26, 2021

Methods and treatment of trauma adverse events with oxygen reduced blood

Inventors: Andrew Dunham (Lexington, MA); Tatsuro Yoshida (Lexington, MA)
Assignee: Hemanext Inc.
A61K35/14A61P7/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,898,517
App. No.
16/791,697
Granted
Jan 26, 2021
Kind
B2
Abstract

Methods for the reversal of hemorrhagic shock or hemorrhagic trauma. Methods for restoring mean arterial pressure to a normal range and reducing trauma adverse risks in a patient through the administration of oxygen reduced blood compositions.

Claims (21)

1. A method for increasing arterial pressure in a hemorrhagic trauma subject in need thereof having a low mean arterial pressure comprising administering stored oxygen reduced blood to said subject, said stored oxygen reduced blood comprising a blood product having a reduced oxygen saturation level prior to storage for a storage period, wherein said low mean arterial pressure in said hemorrhagic trauma subject is increased relative to a patient administered conventionally stored blood.

2. The method of claim 1 , wherein said hemorrhagic trauma subject in need thereof is at risk of developing a hemorrhagic trauma adverse event selected from the group consisting of liver injury, lung failure, kidney failure, and heart failure.

3. The method of claim 1 , wherein said hemorrhagic trauma subject in need thereof comprises decreased hematocrit prior to said administering.

4. The method of claim 1 , wherein said hemorrhagic trauma subject in need thereof comprises an increased lactate level prior to said administering.

5. The method of claim 1 , wherein said hemorrhagic trauma subject in need thereof comprises a glucose level of greater than 200 mg/dL prior to said administering.

6. The method of claim 1 , wherein said subject in need thereof comprises increased aspartate aminotransferase (AST) prior to said administering.

7. The method of claim 1 , wherein said hemorrhagic trauma subject in need thereof comprises increased alanine aminotransferase (ALT) prior to said administering.

8. The method of claim 1 , wherein said hemorrhagic trauma subject in need thereof comprises increased urine neutrophil gelatinase-associated lipocalin (u-NGAL) prior to said administering.

9. The method of claim 1 , wherein said hemorrhagic trauma subject in need thereof comprises increased serum creatinine prior to said administering.

10. The method of claim 1 , wherein said hemorrhagic trauma subject in need thereof comprises increased blood urea nitrogen (BUN) prior to said administering.

11. The method of claim 1 , wherein said stored oxygen reduced blood is depleted to an oxygen saturation of 20% or less prior to said storage period.

12. The method of claim 1 , wherein said stored oxygen reduced blood comprises an oxygen saturation of 20% or less during said storage period.

13. The method of claim 12 , wherein said oxygen reduced blood is also carbon dioxide reduced.

14. The method of claim 1 , wherein said storage period is up to 42 days.

15. The method of claim 1 , wherein said increasing mean arterial pressure in said hemorrhagic trauma subject in need thereof is at a rate faster than the rate of increase of mean arterial pressure in a patient administered conventionally stored blood.

16. The method of claim 1 , wherein said mean arterial pressure is increased by at least 20% after said administering, relative to the mean arterial pressure of a patient transfused with conventionally stored blood.

17. The method of claim 4 , wherein said increased lactate level is reduced to between 0.5 and 2.5 mmol/L after said administering.

18. The method of claim 6 , wherein said increased AST level is reduced by at least 5% after said administering relative to a patient administered conventionally stored blood.

19. The method of claim 7 , wherein said increased ALT level is reduced by at least 5% after said administering relative to a patient administered conventionally stored blood.

20. The method of claim 9 , wherein said increased serum creatinine level is reduced by at least 5% after said administering and relative to a patient administered conventionally stored blood.

21. The method of claim 10 , wherein said increased blood urea nitrogen (BUN) level is reduced by at least 5% after said administering and relative to a patient administered conventionally stored blood.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE PROPERTY NUMBER 16/849,615 PREVIOUSLY RECORDED AT REEL: 54790 FRAME: 499. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 6, 2021
From: DUNHAM, ANDREW
To: HEMANEXT INC.
Reel/Frame 055634/0592 →
CONFIRMATORY ASSIGNMENT Recorded Dec 16, 2020
From: DUNHAM, ANDREW
To: HEMANEXT INC.
Reel/Frame 054790/0499 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2020
From: DUNHAM, ANDREW; YOSHIDA, TATSURO
To: NEW HEALTH SCIENCES, INC.
Reel/Frame 051863/0136 →
CHANGE OF NAME Recorded Feb 19, 2020
From: NEW HEALTH SCIENCES, INC.
To: HEMANEXT INC.
Reel/Frame 051972/0173 →
Continuity (3)
Continuation 16614683
Provisional Application 62508783 · May 19, 2017
Related Publication 20200197438A1 · Jun 25, 2020
Cited By (1)
US 12,582,674